Introduction
Everolimus inhibits the growth of tumor cells and angiogenesis by inhibiting the mTOR (mammalian target of rapamycin) pathway, which is involved in growth of cancer cells and angiogenesis; moreover, it has been reported to cause various adverse reactions such as stomatitis, interstitial pneumonia, infection and metabolic abnormalities [1] [2] [3] [4] [5] . Stomatitis is one of the most common adverse reactions, and may preclude further treatment if it becomes severe. In addition, stomatitis occurs more frequently in Japanese patients according to a report comparing the profile of adverse reactions between Japanese and non−Japanese patients in a phase III global clinical study (RE-CORD−1) 5) . However, the mechanism of the onset of stomatitis has not been elucidated, and appropriate prophylaxis against everolimus− induced stomatitis has not been reported.
In addition, sodium azulene sulfonate, which has anti−inflammatory, mucosal protective, and wound healing effects, is used in the treatment of pharyngitis, tonsillitis, gastrointestinal ulcer and chronic gastritis as well as stomatitis caused by cytocidal antitumor agents in Japan 6)
. We thus examined the prophylactic use of gargling with sodium azulene sulfonate and assessed its ability to prevent stomatitis in patients receiving everolimus. This study is a pilot retrospective study of everolimus of all cases in Yamagata University up to June 2013.
Methods Prophylactic use against stomatitis
In the Department of Urology in our hospital, all patients receive training in oral care techniques (such as dental brushing) from nurses upon admission. In addition, gargling with sodium azulene sulfonate has been used prophylactically against stomatitis in patients receiving mTOR inhibitors since October 2010. At the start of oral treatment with everolimus, patients gargled a solution of one−packet sodium azulene sulfonate granules (Hachiazule Ⓡ 2g/packet) 4 times a day (after every meal and before bedtime). During medication training, they received a full explanation about the prevention of adverse reactions and significance of gargling. Preventive interventions other than the above were not performed. 
Statistical analysis
Comparisons were made between the two groups using the Student' s t−test, Fisher' s exact probability test, and Mann−Whitney U test at a significance level of p＜0.05.
Ethical considerations
The Yamagata University Hospital ethics committee approved this 
Results
The analysis included 21 patients (6 in the non−intervention group and 15 in the intervention group). The intervention group had significantly lower alanine transaminase (ALT) level ( Table 1) . Table 2 ). The time of onset of stomatitis was similar in both groups (non−intervention group: 10.0±7.0 days vs. intervention group: 10.4±2.7 days, mean±SD).
In patients background, incidence of stomatitis in everolimus had no relevance to the onset in prior treatment. Also stomatitis in onset, no obvious infection was observed.
Discussion
Stomatitis is the most common adverse reaction to everolimus [1] [2] [3] [4] [5] , and management of stomatitis is needed to maintain treatment adher- In a global clinical study (RECORD−1), the incidence of adverse reactions to everolimus was higher in Japanese patients than in non− Japanese patients 5) . In particular, the incidence of stomatitis including mouth ulcers was as high as 73％ in Japanese patients 5) , compared with 42.3％ in the entire study population 3) . The incidence of stomatitis in our hospital was 83.3％ in the non−intervention group, which was slightly higher than the incidence in Japanese patients in the RE-CORD−1 study 5) . In addition, the incidence of stomatitis was 71.7％
in a phase II clinical study of everolimus in Japanese patients with advanced gastric cancer 7) , indicating that management of stomatitis is very important to the continuance of treatment 8) . In the present study, the incidence of stomatitis in the intervention group was lower than in Japanese patients in the RECORD−1 study. It suggests that gargling with sodium azulene sulfonate may be useful in preventing stomatitis.
On the other hand, no significant difference was observed in the time of onset of stomatitis between the two groups, showing that the intervention did not delay the onset. It is considered that the difference may become more significant if the observational period is over a longer period of time.
The mechanism underlying everolimus−induced stomatitis has not been fully elucidated, but it may be a T cell−mediated inflammatory disease 9) . It has also been reported that everolimus−induced stomatitis is different from cytocidal anticancer agent−induced oral mucositis, but similar to aphthous stomatitis 3, 10) . As sodium azulene sulfonate has not only an anti−inflammatory effect, but also antihistamine and wound healing effects, these effects may have contributed to inhibition of stomatitis. In Japan, there is no limit on the frequency of gargling with sodium azulene sulfonate, but several times a day is recommended. In the present study, patients were instructed to gargle 4 times a day in order to maintain compliance with everolimus therapy.
The preventive effect may be enhanced by increasing the frequency of gargling once any sign such as strange feeling in the mouth is detected.
Oral care during oral treatment with anticancer agents basically consists of assessment, patient education, dental brushing and flossing, and gargling with physiological saline or sodium bicarbonate 9, 10) , and oral care during oral treatment with everolimus is basically the same 11, 12) . Oral care plays a fundamental role in the maintenance of the health of the oral mucosa, and thereby reduces the risk of oral complications 13) . In our hospital, oral care training preceded the introduction of the prophylactic use of gargling, but stomatitis frequently occurred early on, indicating that oral care education may not be sufficient to prevent stomatitis. This may be partly due to poor patient compliance with oral care.
In this study, most of the patients who developed stomatitis have been treated with topical steroids. Since everolimus has an immunosuppressive effect, mucosal barrier breakdown associated with stomatitis may increase the risk of secondary stomatitis. It is therefore very important to maintain oral hygiene. Although stomatitis did not lead to treatment discontinuation or dose reduction in our study, dose reduction has been reported in several patients in the past. Stomatitis in these patients was controlled by treatment with topical steroids 8) . It is thus suggested that stomatitis can be managed more effectively by following a protocol combining prophylactic gargling and treatment with topical steroids.
This study demonstrated that gargling with sodium azulene sulfonate successfully inhibited stomatitis. In addition, its use as a self−care intervention allows oral everolimus to be given on an outpatient basis.
Therefore, instruction should be individualized according to the patient' s background to enhance compliance with oral care. Future, in order to focus on prevention, we will consider to run prospective randomized clinical trial with unite patient's background. 
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